Phosphate substitution in an AlOOH - TLR4 adjuvant system (SPA08) modulates the immunogenicity of Serovar E MOMP from Chlamydia trachomatis

References

• Vodstrcil LA, McIver R, Huston WM, Tabrizi SN, Timms P, Hocking JS. The Epidemiology of Chlamydia trachomatis Organism Load During Genital Infection: A Systematic Review. J Infect Dis 2015; 211(10):1628-45; PMID:25492913; http://dx.doi.org/10.1093/infdis/jiu670
   PubMed Web of Science ®Google Scholar
• Hafner LM, Wilson DP, Timms P. Development status and future prospects for a vaccine against Chlamydia trachomatis infection. Vaccine 2014; 32(14):1563-71; PMID:23973245; http://dx.doi.org/10.1016/j.vaccine.2013.08.020
   PubMed Web of Science ®Google Scholar
• Darville T, O'Neill JM, Andrews CW, Jr., Nagarajan UM, Stahl L, Ojcius DM. Toll-like receptor-2, but not Toll-like receptor-4, is essential for development of oviduct pathology in chlamydial genital tract infection. J Immunol 2003; 171(11):6187-97; PMID:14634135; http://dx.doi.org/10.4049/jimmunol.171.11.6187
   PubMed Web of Science ®Google Scholar
• Fichorova RN, Cronin AO, Lien E, Anderson DJ, Ingalls RR. Response to Neisseria gonorrhoeae by cervicovaginal epithelial cells occurs in the absence of toll-like receptor 4-mediated signaling. J Immunol 2002; 168(5):2424-32; PMID:11859134; http://dx.doi.org/10.4049/jimmunol.168.5.2424
   PubMed Web of Science ®Google Scholar
• Massari P, Toussi DN, Tifrea DF, de la Maza LM. Toll-like receptor 2-dependent activity of native major outer membrane protein proteosomes of Chlamydia trachomatis. Infect Immun 2013; 81(1):303-10; PMID:23132491; http://dx.doi.org/10.1128/IAI.01062-12
   PubMed Web of Science ®Google Scholar
• Pioli PA, Amiel E, Schaefer TM, Connolly JE, Wira CR, Guyre PM. Differential expression of Toll-like receptors 2 and 4 in tissues of the human female reproductive tract. Infect Immun 2004; 72(10):5799-806; PMID:15385480; http://dx.doi.org/10.1128/IAI.72.10.5799-5806.2004
   PubMed Web of Science ®Google Scholar
• Farris CM, Morrison RP. Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model. Infect Immun 2011; 79(3):986-96; PMID:21078844; http://dx.doi.org/10.1128/IAI.00881-10
   PubMed Web of Science ®Google Scholar
• Pal S, Peterson EM, de la Maza LM. Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria. Infect Immun 2005; 73(12):8153-60; PMID:16299310; http://dx.doi.org/10.1128/IAI.73.12.8153-8160.2005
   PubMed Web of Science ®Google Scholar
• Tagliabue A, Rappuoli R. Vaccine adjuvants: the dream becomes real. Hum Vaccin 2008; 4(5):347-9; PMID:18682690; http://dx.doi.org/10.4161/hv.4.5.6438
   PubMed Web of Science ®Google Scholar
• Fox CB, Friede M, Reed SG, Ireton GC. Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants. Subcell Biochem 2010; 53:303-21; PMID:20593273; http://dx.doi.org/10.1007/978-90-481-9078-2_14
   PubMedGoogle Scholar
• Hansen B, Sokolovska A, Hogenesch H, Hem SL. Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response. Vaccine 2007; 25(36):6618-24; PMID:17681647; http://dx.doi.org/10.1016/j.vaccine.2007.06.049
   PubMed Web of Science ®Google Scholar
• Hansen B, Belfast M, Soung G, Song L, Egan PM, Capen R, Hogenesch H, Mancinelli R, Hem SL. Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response. Vaccine 2009; 27(6):888-92; PMID:19071182; http://dx.doi.org/10.1016/j.vaccine.2008.11.078
   PubMed Web of Science ®Google Scholar
• Hem SL, Hogenesch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines 2007; 6(5):685-98; PMID:17931150; http://dx.doi.org/10.1586/14760584.6.5.685
   PubMed Web of Science ®Google Scholar
• Hogenesch H, Dunham A, Hansen B, Anderson K, Maisonneuve JF, Hem SL. Formulation of a killed whole cell pneumococcus vaccine - effect of aluminum adjuvants on the antibody and IL-17 response. J Immune Based Ther Vaccines 2011; 9:5; PMID:21801401; http://dx.doi.org/10.1186/1476-8518-9-5
   PubMedGoogle Scholar
• Ishizaka ST, Hawkins LD. E6020: a synthetic Toll-like receptor 4 agonist as a vaccine adjuvant. Expert Rev Vaccines 2007; 6(5):773-84; PMID:17931157; http://dx.doi.org/10.1586/14760584.6.5.773
   PubMed Web of Science ®Google Scholar
• Byrne GI, Stephens RS, Ada G, Caldwell HD, Su H, Morrison RP, Van der Pol B, Bavoil P, Bobo L, Everson S. Workshop on in vitro neutralization of Chlamydia trachomatis: summary of proceedings. J Infect Dis 1993; 168(2):415-20; PMID:8335979; http://dx.doi.org/10.1093/infdis/168.2.415
   PubMed Web of Science ®Google Scholar
• Stary G, Olive A, Radovic-Moreno AF, Gondek D, Alvarez D, Basto PA, Perro M, Vrbanac VD, Tager AM, Shi J, et al. VACCINES. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells. Science 2015; 348(6241):aaa8205; PMID:26089520; http://dx.doi.org/10.1126/science.aaa8205
   PubMed Web of Science ®Google Scholar
• Garcon N, Morel S, Didierlaurent A, Descamps D, Wettendorff M, Van MM. Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach. BioDrugs 2011; 25(4):217-226; PMID:21815697; http://dx.doi.org/10.2165/11591760-000000000-00000
   PubMed Web of Science ®Google Scholar
• O'Hagan DT, Fox CB. New generation adjuvants–from empiricism to rational design. Vaccine 2015; 33(Suppl 2):B14-20; PMID:26022561; http://dx.doi.org/10.1016/j.vaccine.2015.01.088
   PubMedGoogle Scholar
• Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kielland A, Vosters O, Vanderheyde N, Schiavetti F, et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009; 183(10):6186-97; PMID:19864596; http://dx.doi.org/10.4049/jimmunol.0901474
   PubMed Web of Science ®Google Scholar
• Duthie MS, Windish HP, Fox CB, Reed SG. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 2011; 239(1):178-96; PMID:21198672; http://dx.doi.org/10.1111/j.1600-065X.2010.00978.x
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005; 310(5753):1510-2; PMID:16322460; http://dx.doi.org/10.1126/science.1118948
   PubMed Web of Science ®Google Scholar
• Wei L, Laurence A, Elias KM, O'Shea JJ. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem 2007; 282(48):34605-10; PMID:17884812; http://dx.doi.org/10.1074/jbc.M705100200
   PubMed Web of Science ®Google Scholar
• Wurster AL, Rodgers VL, Satoskar AR, Whitters MJ, Young DA, Collins M, Grusby MJ. Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon gamma-producing Th1 cells. J Exp Med 2002; 196(7):969-77; PMID:12370258; http://dx.doi.org/10.1084/jem.20020620
   PubMed Web of Science ®Google Scholar
• Mitsdoerffer M, Lee Y, Jager A, Kim HJ, Korn T, Kolls JK, Cantor H, Bettelli E, Kuchroo VK. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc Natl Acad Sci U S A 2010; 107(32):14292-7; PMID:20660725; http://dx.doi.org/10.1073/pnas.1009234107
   PubMed Web of Science ®Google Scholar
• Murphy K, Travers P, Walport P. Janeway's Immunobiology; 7 ed.; Garland Science: New York, 2008.pp. 865
   Google Scholar
• Pape KA, Catron DM, Itano AA, Jenkins MK. The humoral immune response is initiated in lymph nodes by B cells that acquire soluble antigen directly in the follicles. Immunity 2007; 26(4):491-502; PMID:17379546; http://dx.doi.org/10.1016/j.immuni.2007.02.011
   PubMed Web of Science ®Google Scholar
• Brookes RH, Hakimi J, Ha Y, Aboutorabian S, Ausar SF, Hasija M, Smith SG, Todryk SM, Dockrell HM, Rahman N. Screening vaccine formulations for biological activity using fresh human whole blood. Hum Vaccin Immunother 2014; 10(4):1129-35; PMID:24401565; http://dx.doi.org/10.4161/hv.27657
   PubMed Web of Science ®Google Scholar
• Garcon N. Preclinical development of AS04. Methods Mol Biol 2010; 626:15-27; PMID:20099118; http://dx.doi.org/10.1007/978-1-60761-585-9_2
   PubMedGoogle Scholar
• Morefield GL, Hawkins LD, Ishizaka ST, Kissner TL, Ulrich RG. Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome. Clin Vaccine Immunol 2007; 14(11):1499-504; PMID:17715328; http://dx.doi.org/10.1128/CVI.00153-07
   PubMed Web of Science ®Google Scholar
• Ljutic B, Ochs M, Messham B, Ming M, Dookie A, Harper K, Ausar SF. Formulation, stability and immunogenicity of a trivalent pneumococcal protein vaccine formulated with aluminum salt adjuvants. Vaccine 2012; 30(19):2981-8; PMID:22381074; http://dx.doi.org/10.1016/j.vaccine.2012.02.038
   PubMed Web of Science ®Google Scholar